 |
|
|
|
Presentation
An inactivated adjuvanted liquid vaccine of Mycoplasma hyopneumoniae.
Uses
For the vaccination of healthy, susceptible immune competent piglets as an aid in the prevention of respiratory disease associated with Mycoplasma. hyopneumoniae, Mycoplasma Induced Respiratory Disease (MIRD).
For use in growing pigs only from one week of age.
|
|
Dosage and administration
Shake well before use.
2 ml should be administered by intramuscular injection. Minimum age at first inoculation one week.
A course of two injections two weeks apart is recommended from one to ten weeks of age.
The second injection should be administered at least three weeks before the expected field challenge occurs.
|
|
Contra-indications, warnings, etc
FOR ANIMAL TREATMENT ONLY
Not for use in pregnant animals.
Only healthy pigs should be vaccinated.
Aseptic precautions should be observed.
Use entire contents when first opened.
Syringes should not have been sterilised chemically or be above ambient temperature.
Dispose of used container by incineration or after immersion in an approved disinfectant ( eg Halamid).
Do not administer within 14 days of other vaccinations as compatibility has not been investigated.
Animals that have received immunosuppressive drugs (eg glucocorticoids) should not be vaccinated until an interval of at least 4 weeks has elapsed.
Pharmaceutical precautions
Store at +2°C to +8°C and use before the expiry date printed on the pack. Do not freeze. Protect from light. Keep out of the reach of children.
|
|
Legal category
POM-V (previously POM).
Packaging Quantities
50 dose (100 ml) and 125dose (250 ml) plastic packs.
Further information
Vaccine should be used only as a tool for disease control together with environmental management and medication practices designed to minimise the incidence of disease caused by Mycoplasma Hyopneumoniae.
In any animal population there will be a small number of individuals which fail to respond fully to vaccination. Successful vaccination depends upon correct storage and administration of the vaccine and the animal's ability to respond. Immune competence can be influenced by genetic factors, intercurrent infection, age, nutritional status, concurrent drug therapy, stress, etc.
Maternally derived antibody (MDA) can interfere with the development of active immunity. Where it is likely that recent field infection or vaccination of the dam has stimulated a high antibody titre and consequently a high level of MDA, the timing of the vaccination programme should be planned accordingly.
Immunocompetence in the pig increases with age. Age at vaccination should be determined by consideration of the timing of field challenge. For example, earlier vaccination is recommended where early challenge is expected.
Evidence has been obtained from field trials that the vaccine has a protective effect up until slaughter at 30 weeks of age, when piglets in infected herds are vaccinated as recommended.
Selection of herds where vaccine use is appropriate and continued monitoring should be carried out by the supervising veterinary surgeon.
It is good practice to allow vaccine to warm to body temperature in the hand or pocket before administration, to avoid the discomfort of injections of a cold liquid.
Product licence number
Vm 01596/4149
|
|
|
